Zacks Investment Research
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics shares surged 31.5% to $14.45 after the company raised its full-year 2026 revenue guidance to $410-$420 million from $350-$370 million. The stock is expected to report quarterly revenues of $106.85 million (up 58.4% year-over-year) with a loss of $0.12 per share. However, analysts note that without recent earnings estimate revisions, the stock's momentum may not sustain, and the company carries a Zacks Rank #3 (Hold) rating.
